Related Experiment Videos
Second generation aromatase inhibitor--4-hydroxyandrostenedione
1Academic Dept of Biochemistry, Royal Marsden Hospital, London, UK.
Breast Cancer Research and Treatment
|January 1, 1994
Summary
The steroidal drug 4-hydroxyandrostenedione effectively inhibits aromatase in postmenopausal breast cancer patients. It shows minimal side effects and offers a new treatment option, particularly when administered intramuscularly.
Area of Science:
- Endocrinology
- Oncology
- Pharmacology
Background:
- Aromatase inhibitors are crucial in treating hormone-sensitive breast cancer.
- 4-hydroxyandrostenedione is a steroidal inhibitor of the aromatase enzyme.
- Previous studies have evaluated its efficacy in postmenopausal breast cancer.
Purpose of the Study:
- To assess the efficacy and tolerability of 4-hydroxyandrostenedione in postmenopausal breast cancer.
- To determine optimal dosing and administration routes for clinical use.
- To evaluate its role as a second-line therapy after tamoxifen treatment.
Main Methods:
- Intramuscular administration of 250 mg 4-hydroxyandrostenedione every two weeks.
- Measurement of peripheral aromatase inhibition and oestradiol suppression.
- Evaluation of response rates and side effects in unselected patients.
Main Results:
- Achieved approximately 85% peripheral aromatase inhibition and 65% oestradiol suppression.
- Demonstrated an overall response rate of 26% in patients treated second-line.
- Reported minimal side effects, primarily local reactions at the injection site.
Conclusions:
- 4-hydroxyandrostenedione is an effective and well-tolerated selective aromatase inhibitor.
- Its intramuscular administration provides significant hormonal suppression.
- Represents a valuable new therapeutic option for postmenopausal breast cancer patients.